PMV PHARMACEUTICALS INC
PMV Pharmaceuticals Inc (ticker: PMVP) is a small-cap biopharmaceutical company (market cap about $81.08M). Companies at this stage typically focus on developing and commercialising novel therapeutics and may have limited revenue, early-stage clinical programmes and dependence on partnerships, licensing or additional funding. Key things an investor should know include the binary nature of drug development — clinical results and regulatory decisions can move the share price sharply — and that trading liquidity may be low, increasing volatility. Investment time horizons are often long, while financing rounds can dilute existing shareholders. For general education, monitor clinical updates, regulatory filings, partnership announcements and cash runway. This is general information, not personalised advice; biopharma investments carry material risk and may not be suitable for all investors.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying PMV Pharmaceuticals' stock with a target price of $8.5, indicating growth potential.
Financial Health
PMV Pharmaceuticals is showing strong cash generation and solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PMVP
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketThe Post-Pandemic Pediatric Pivot
The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.
Published: August 13, 2025
Explore BasketBeyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: August 5, 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: July 11, 2025
Explore BasketPersonalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage catalyst watch
Clinical data releases and regulatory updates can be major catalysts. These events are high-impact but outcomes are uncertain, so expect potential volatility.
Volatility and liquidity
With a modest market cap, share prices can move sharply and trading volumes may be low. Consider position sizing and diversification to manage risk.
Funding and partnerships
Partnerships or financing rounds often shape a company’s progress and valuation. Such developments can reduce risk or dilute shares, so monitor announcements closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
